MARKET

STTK

STTK

Shattuck Labs, Inc.
NASDAQ
6.37
+0.25
+4.09%
After Hours: 6.33 -0.04 -0.63% 18:24 03/25 EDT
OPEN
6.12
PREV CLOSE
6.12
HIGH
6.59
LOW
6.12
VOLUME
631.19K
TURNOVER
--
52 WEEK HIGH
6.59
52 WEEK LOW
0.6922
MARKET CAP
455.86M
P/E (TTM)
-9.0818
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at STTK last week (0316-0320)?
Weekly Report · 2d ago
Weekly Report: what happened at STTK last week (0309-0313)?
Weekly Report · 03/16 09:47
Shattuck Labs Is Maintained at Neutral by Citigroup
Dow Jones · 03/13 20:17
Shattuck Labs Price Target Raised to $7.00/Share From $4.00 by Citigroup
Dow Jones · 03/13 20:17
Citigroup Maintains Neutral on Shattuck Labs, Raises Price Target to $7
Benzinga · 03/13 20:07
Analysts Have Conflicting Sentiments on These Healthcare Companies: Shattuck Labs (STTK), Oruka Therapeutics (ORKA) and Option Care Health (OPCH)
TipRanks · 03/13 11:20
Citi ups Shattuck Labs target, opens ‘upside 90-day catalyst watch’
TipRanks · 03/13 10:50
Weekly Report: what happened at STTK last week (0302-0306)?
Weekly Report · 03/09 09:48
More
About STTK
Shattuck Labs, Inc. is a biotechnology company. The Company is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The Company is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. It is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.

Webull offers Shattuck Labs Inc stock information, including NASDAQ: STTK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, STTK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading STTK stock methods without spending real money on the virtual paper trading platform.